Nothing Special   »   [go: up one dir, main page]

MX2020008446A - Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. - Google Patents

Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.

Info

Publication number
MX2020008446A
MX2020008446A MX2020008446A MX2020008446A MX2020008446A MX 2020008446 A MX2020008446 A MX 2020008446A MX 2020008446 A MX2020008446 A MX 2020008446A MX 2020008446 A MX2020008446 A MX 2020008446A MX 2020008446 A MX2020008446 A MX 2020008446A
Authority
MX
Mexico
Prior art keywords
antibodies
treating cancer
methods
binding fragment
ctla4
Prior art date
Application number
MX2020008446A
Other languages
English (en)
Inventor
Rachel Allison Altura
Mallika Lala
Lokesh Jain
Mengyao Li
Archie Ngai-Chiu Tse
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2020008446A publication Critical patent/MX2020008446A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento contra el cáncer en un paciente, que comprenden administrar al paciente un anticuerpo anti-PD-1 o fragmento de unión a antígeno del mismo en cantidades específicas aproximadamente cada seis semanas, combinado administrar un anticuerpo anti-CTLA4 al paciente aproximadamente cada seis semanas. En determinadas modalidades, el antagonista de PD-1 es pembrolizumab o un fragmento de unión a antígeno del mismo. También se proporcionan composiciones que comprenden una dosificación de un anticuerpo anti-PD-1, o fragmento de unión a antígeno del mismo, y una dosificación de un anticuerpo anti-CTLA4 o fragmento de unión a antígeno del mismo, y usos del mismo para el tratamiento contra el cáncer.
MX2020008446A 2018-02-13 2019-02-08 Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. MX2020008446A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862630038P 2018-02-13 2018-02-13
US201862732828P 2018-09-18 2018-09-18
US201862740741P 2018-10-03 2018-10-03
PCT/US2019/017188 WO2019160755A1 (en) 2018-02-13 2019-02-08 Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies

Publications (1)

Publication Number Publication Date
MX2020008446A true MX2020008446A (es) 2020-09-28

Family

ID=67620098

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008446A MX2020008446A (es) 2018-02-13 2019-02-08 Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.

Country Status (11)

Country Link
US (1) US20210047409A1 (es)
EP (1) EP3752193A4 (es)
JP (2) JP2021513540A (es)
KR (1) KR20200119845A (es)
CN (1) CN111727056A (es)
AU (2) AU2019222517A1 (es)
BR (1) BR112020015915A8 (es)
CA (1) CA3090996A1 (es)
MA (1) MA51844A (es)
MX (1) MX2020008446A (es)
WO (1) WO2019160755A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100054780A (ko) 2007-06-18 2010-05-25 엔.브이.오가논 사람 프로그램된 사멸 수용체 pd-1에 대한 항체
CN113244385A (zh) * 2020-02-07 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗恶性肿瘤中的用途
WO2021178611A1 (en) * 2020-03-05 2021-09-10 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-ctla4 antibody, and an anti-tigit antibody
WO2021178657A1 (en) * 2020-03-05 2021-09-10 Merck Sharp & Dohme Corp. Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof
WO2021213523A1 (zh) * 2020-04-24 2021-10-28 信达生物制药(苏州)有限公司 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
TW202305009A (zh) * 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
KR20240099187A (ko) * 2021-10-29 2024-06-28 온코씨4, 아이앤씨. 항-ctla-4 항체 투여 요법
CN113933520B (zh) * 2021-11-15 2023-06-20 邹灵龙 一种通用型抗体药血药浓度检测的单克隆抗体试剂组合、检测方法和试剂盒
WO2024002074A1 (zh) * 2022-06-28 2024-01-04 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
WO2024055005A2 (en) * 2022-09-09 2024-03-14 Adagene Pte. Ltd. Activatable anti-ctla4 antibodies for treating cancer
CN118767127A (zh) * 2023-04-10 2024-10-15 康方药业有限公司 抗ctla4-抗pd-1双特异性抗体的医药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1212422T3 (da) * 1999-08-24 2007-07-02 Medarex Inc Humane CTLA-4-antistoffer og anvendelserne deraf
WO2006121168A1 (en) * 2005-05-09 2006-11-16 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR20100054780A (ko) * 2007-06-18 2010-05-25 엔.브이.오가논 사람 프로그램된 사멸 수용체 pd-1에 대한 항체
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
CN105296433B (zh) * 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
CA2955676A1 (en) * 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
WO2016176504A1 (en) * 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
DK3322731T3 (da) * 2015-07-14 2021-03-08 Bristol Myers Squibb Co Fremgangsmåde til behandling af cancer ved hjælp af immun checkpoint-hæmmer; antistof der binder til programmed death-1-receptor (pd-1) eller programmed death ligand-1 (pd-l1)
WO2017021911A1 (en) * 2015-08-04 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP3331919A1 (en) * 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
KR20180088907A (ko) * 2015-12-17 2018-08-07 노파르티스 아게 Pd-1에 대한 항체 분자 및 그의 용도
US10358496B2 (en) * 2016-03-01 2019-07-23 Ralf Kleef Low dose immune checkpoint blockade in metastatic cancer
EP4248990A3 (en) * 2016-06-02 2024-01-03 Bristol-Myers Squibb Company Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma
JP2019517512A (ja) * 2016-06-03 2019-06-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 結腸直腸癌を有する患者の処置における抗pd−1抗体の使用
EP3464369A1 (en) * 2016-06-03 2019-04-10 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treating a tumor
CN110678199A (zh) * 2017-05-02 2020-01-10 默沙东公司 单独的和与程序性死亡受体1(pd-1)抗体组合的抗ctla4抗体的稳定制剂及其使用方法

Also Published As

Publication number Publication date
US20210047409A1 (en) 2021-02-18
RU2020129075A (ru) 2022-03-14
CA3090996A1 (en) 2019-08-22
WO2019160755A1 (en) 2019-08-22
AU2023208115A1 (en) 2024-01-18
MA51844A (fr) 2021-05-19
JP2024038250A (ja) 2024-03-19
KR20200119845A (ko) 2020-10-20
JP2021513540A (ja) 2021-05-27
CN111727056A (zh) 2020-09-29
BR112020015915A8 (pt) 2023-01-31
EP3752193A4 (en) 2022-02-23
EP3752193A1 (en) 2020-12-23
AU2019222517A1 (en) 2020-08-13
BR112020015915A2 (pt) 2020-12-15

Similar Documents

Publication Publication Date Title
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
NZ769968A (en) Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
BR112018012801A2 (pt) combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 para tratar o câncer
CR20200467A (es) Agentes anticuerpos anti-cd25
MX2020012567A (es) Anticuerpos anti-ox40 y metodos de uso.
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
PH12020552115A1 (en) Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies
GEP20207166B (en) Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use
MX2017005976A (es) Moleculas de union especificas para grupo de diferenciacion 73 (cd73) y usos de las mismas.
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
EA201992526A1 (ru) Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2024000780A (es) Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon.
RU2014147867A (ru) Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
AU2018290532A1 (en) Immunotherapy for hepatocellular carcinoma
EA201990374A1 (ru) Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков
MX2021009041A (es) Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
MX2021004226A (es) Terapia combinada contra el cáncer.
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2021008760A (es) Anticuerpo anti-cd79b, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
MX2022008421A (es) Anticuerpo anti-galectina-9 y usos del mismo.
PH12020551451A1 (en) Anti-cd25 for tumour specific cell depletion